目录产品 » CD229/SLAMF3 mFc Chimera, Human
Manual
SDS
COAs

CD229/SLAMF3 mFc Chimera, Human

CD229 was strongly and homogeneously overexpressed on the PC of patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, MM, and PC leukemia. CD229 was particularly overexpressed on those PC showing an abnormal phenotype such as expression of CD56. Most importantly, CD229 was also highly expressed on those cells in the patients' BM displaying the phenotype of chemotherapy-resistant and myeloma-propagating cells.
￥4100
Z05130-100

产品简介
Species Human
Protein Construction
CD229/SLAMF3 (Lys364-Asp452)_x000D_
Accession # Q9HBG7-1		 mFc (IgG1)
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 35.56 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Concentration Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background CD229 was strongly and homogeneously overexpressed on the PC of patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, MM, and PC leukemia. CD229 was particularly overexpressed on those PC showing an abnormal phenotype such as expression of CD56. Most importantly, CD229 was also highly expressed on those cells in the patients' BM displaying the phenotype of chemotherapy-resistant and myeloma-propagating cells.
Synonyms SLAMF3; CD229; LY9; AI893573; Lgp100; T100
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.